Danish Study Confirms Safety of JN.1-Updated COVID-19 mRNA Vaccines in Real-World Analysis

A large-scale Danish cohort study has provided reassuring real-world safety data for JN.1-updated mRNA COVID-19 (搜索)搜索该疾病 vaccines, finding no increased risk of serious adverse events in over 1 million vaccinated adults. The research, published in JAMA Network Open by Andersson et al, represents the most comprehensive safety evaluation to date of variant-specific vaccines targeting the SARS-CoV-2 (搜索)搜索该疾病 Omicron JN.1 lineage.

The emergence of the JN.1 lineage, classified as part of the KP.2 subvariant family, prompted urgent regulatory responses in late 2024, with updated mRNA vaccines authorized in the United States and Europe for the 2024-2025 booster campaign. However, real-world safety data on these variant-specific vaccines remained limited until this comprehensive analysis.

Study Design and Population

The retrospective cohort study leveraged Denmark's national health data infrastructure, linking records from the Danish Civil Registration System, Danish Vaccination Register, and the National Patient Register. The study population included all adults 18 years and older who met government criteria for receiving a JN.1-containing booster—specifically individuals 65 years and older or those categorized as high-risk due to comorbidities.

Of the 1,585,883 eligible adults, 1,012,400 received the updated JN.1 vaccine during the follow-up period from May 1, 2024, to March 31, 2025. The mean age of vaccinated individuals was 73.5 years, with 54.4% being female. The majority (86.7%) were prioritized due to age rather than underlying high-risk conditions. Common comorbidities included chronic cardiac disorders (20.3%), autoimmune conditions (8.5%), diabetes (搜索)搜索该疾病 (6.4%), and malignancy (9.9%).

Comprehensive Safety Assessment

The investigators focused on 29 predefined serious adverse events of special interest (AESIs), compiled from sources including the Brighton Collaboration (搜索)搜索该词条 and FDA's Biologics Effectiveness and Safety Initiative. These included cardiovascular conditions such as ischemic cardiac events and myocarditis (搜索)搜索该疾病, thrombotic events like pulmonary embolism (搜索)搜索该疾病 and deep vein thrombosis, neurological syndromes including Guillain-Barré syndrome (搜索)搜索该疾病 and seizures, autoimmune and inflammatory conditions, and organ-specific failures.

Vaccination status was treated as a time-varying covariate, with each individual contributing person-time to both the "risk period" (28 days post-vaccination) and "reference period" (person-time outside the 28-day window). A 14-day buffer period was excluded from analysis to mitigate time-related confounding.

Key Safety Findings

The central conclusion of the study is that no statistically significant increases in adverse event rates were observed in the 28 days following vaccination with JN.1-containing mRNA vaccines. Several incidence rate ratios (IRRs) actually suggested lower event rates during the risk period, though the study authors caution that causality should not be inferred from these associations.

Notable results include:

• Ischemic cardiac events: IRR of 0.84 (95% CI, 0.76-0.94)
• Cerebrovascular events: IRR of 0.84 (95% CI, 0.77-0.92)
• Pulmonary embolism: IRR of 0.75 (95% CI, 0.62-0.90)
• Acute kidney injury: IRR of 0.67 (95% CI, 0.59-0.77)
• Myocarditis: IRR of 1.12 (95% CI, 0.41-3.10), not statistically significant
• Pericarditis: IRR of 0.42 (95% CI, 0.20-0.89)

For three outcomes—cerebral venous thrombosis, transverse myelitis, and narcolepsy—no events occurred in the risk period, precluding estimation of IRRs. Importantly, the upper bounds of the confidence intervals for 19 of the 29 adverse events were inconsistent with even moderate (≥1.5-fold) increases in risk.

Clinical and Public Health Implications

These results build upon prior evaluations of earlier Omicron-adapted vaccines targeting BA.1, BA.4/5, and XBB.1.5 lineages, which similarly demonstrated no elevated risks for serious adverse events. The JN.1 lineage, which rose to dominance globally in late 2024, shares spike protein (搜索)搜索该靶点 mutations associated with immune escape, raising concerns about the need for vaccine updates.

From a managed care and public health perspective, these findings are crucial as vaccination fatigue and hesitancy continue to impact booster uptake, particularly among older and high-risk populations. Robust safety data remain vital to maintaining trust in public immunization programs.

Recent preclinical research by Ao et al further supports the rationale for JN.1-specific updates, demonstrating that a JN.1-mRNA vaccine查看药品详情 elicited robust, long-lasting humoral and cellular immune responses in animal models, with enhanced neutralizing activity against JN.1 and KP.3 variants.

Study Limitations

The researchers acknowledge several important limitations. Residual confounding remains a concern despite the use of within-individual comparisons to mitigate bias. The study was underpowered to assess very rare events, and the 28-day follow-up period may not capture adverse events with longer latency periods. Additionally, because the study population was restricted to adults eligible for Denmark's national JN.1 booster program, the findings may not be generalizable to younger, healthier populations.

The comprehensive analysis offers timely reassurance about the safety of JN.1-updated mRNA COVID-19 (搜索)搜索该疾病 vaccines, reinforcing the favorable safety profile of mRNA technology even as antigenic targets evolve. These findings hold particular relevance for managed care organizations, public health authorities, and policymakers navigating updated booster campaigns amid growing public skepticism and pandemic fatigue.